Production (Stage)
Aspire Biopharma Holdings, Inc.
ASBP
$0.225
$0.0010.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 121.69% | 122.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 122.51% | 164.01% | |||
| Operating Income | -122.51% | -164.01% | |||
| Income Before Tax | -2,058.61% | -204.41% | |||
| Income Tax Expenses | -- | -100.00% | |||
| Earnings from Continuing Operations | -2,058.61% | -203.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2,058.61% | -203.16% | |||
| EBIT | -122.51% | -164.01% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -24,647.06% | -240.00% | |||
| Normalized Basic EPS | -2,890.00% | -233.33% | |||
| EPS Diluted | -24,647.06% | -240.00% | |||
| Normalized Diluted EPS | -2,890.00% | -233.33% | |||
| Average Basic Shares Outstanding | -91.39% | -0.75% | |||
| Average Diluted Shares Outstanding | -91.39% | -0.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||